Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,542.88
(
-1.04%
)
US TECH 100
23,195.20
(
-1.46%
)
Dow Jones
46,234.57
(
-0.93%
)
Brent Oil
107.94
(
0.81%
)
Bitcoin
68,144.23
(
-1.04%
)
News Focus
News Focus
Post# of 257368
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: DonShimoda post# 127344

Monday, 09/26/2011 11:19:28 AM

Monday, September 26, 2011 11:19:28 AM

Post# of 257368
It's worth noting that the 63% CCyR response for pona in 3rd-line patients is quite comparable to the 66% figure for Gleevec in 1st-line patients.

This drug really does look to be best in class. I'm guessing that for 1st-line patients a lower dose (30mg) will work fine, and so the practical side-effect profile could potentially improve even further.

Peter
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today